Author: Editor

Nadine Tung, MD of Dana Farber/Harvard Cancer Center @DanaFarber @Harvard discusses a phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes presented at this year’s virtual ASCO.

Nadine Tung, MD of Dana Farber/Harvard Cancer Center @DanaFarber @Harvard discusses a phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes presented at this year’s virtual ASCO.

Nadine Tung, MD of Dana Farber/Harvard Cancer Center @DanaFarber @Harvard discusses a phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes presented at this year’s virtual ASCO.

Prof. Laura Van ‘T Veer, Ph.D., Cheif Research Officer (CRO) and Co-Founder of Agendia and UCSF Helen Diller Family Cancer Center @UCSFMedicine discusses MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients presented at this year’s virtual ASCO.

Prof. Laura Van ‘T Veer, Ph.D., Cheif Research Officer (CRO) and Co-Founder of Agendia and UCSF Helen Diller Family Cancer Center @UCSFMedicine discusses MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/184901/abstract

Prof. Laura Van ‘T Veer, Ph.D., Cheif Research Officer (CRO) and Co-Founder of Agendia and UCSF Helen Diller Family Cancer Center @UCSFMedicine discusses MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/184901/abstract

Keyan Salari, MD @KeyanSalari of Massachusetts General Hospital @MGHUrology discusses 5-alpha reductase inhibitors and risk of overall and fatal bladder cancer.

Keyan Salari, MD @KeyanSalari of Massachusetts General Hospital @MGHUrology discusses 5-alpha reductase inhibitors and risk of overall and fatal bladder cancer.

George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving viagenpumatucel-L plus nivolumab. Read here: https://www.heatbio.com/news-media/news-releases/detail/660/heat-biologics-presents-positive-survival-benefit-for

George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving viagenpumatucel-L plus nivolumab. Read here: https://www.heatbio.com/news-media/news-releases/detail/660/heat-biologics-presents-positive-survival-benefit-for

George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving viagenpumatucel-L plus nivolumab. Read here: https://www.heatbio.com/news-media/news-releases/detail/660/heat-biologics-presents-positive-survival-benefit-for

George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving viagenpumatucel-L plus nivolumab. Read here: https://www.heatbio.com/news-media/news-releases/detail/660/heat-biologics-presents-positive-survival-benefit-for

George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving viagenpumatucel-L plus nivolumab. Read here: https://www.heatbio.com/news-media/news-releases/detail/660/heat-biologics-presents-positive-survival-benefit-for

Henry Gómez of Oncosalud – AUNA discusses real-world evidence shows for the first time the practice-changing impact of TAILORx results. Read here: https://www.exactsciences.com/newsroom/new-oncotype-dx-data-asco2020  

Henry Gómez of Oncosalud – AUNA discusses real-world evidence shows for the first time the practice-changing impact of TAILORx results. Read here: https://www.exactsciences.com/newsroom/new-oncotype-dx-data-asco2020

Earn CME: https://www.naccme.com/program/20-hemcovid-4 In this webcast, Drs. Joseph R. Mikhael leads a roundtable discussion with Drs. Jessica K. Altman, Michael Angarone, Matthew R. Levine, and Mary-Beth Percival and patient advocate Yelak Biru about management challenges faced by healthcare practitioners as they manage patients with hematologic malignancies during the COVID-19 pandemic, with a focus on the patient experience. © 2020 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/20-hemcovid-3 In this webcast, Drs. Joseph R. Mikhael and Nina Shah discuss challenges faced by US healthcare practitioners as they manage the treatment of patients with myeloma during the COVID-19 pandemic. © 2020 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/20-hemcovid-2 In this webcast, Drs. Joseph R. Mikhael and John P. Leonard discuss challenges faced by US healthcare practitioners as they manage the treatment of patients with lymphoma during the COVID-19 pandemic. © 2020 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/20-hemcovid-1 In this webcast, Drs. Joseph R. Mikhael, John P. Leonard, Nina Shan, and Michael J. Satlin discuss challenges faced by US healthcare practitioners as they manage the treatment of patients with hematologic malignancies during the COVID-19 pandemic. © 2020 Imedex, an HMP Company

Henry Gómez of Oncosalud – AUNA discusses real-world evidence shows for the first time the practice-changing impact of TAILORx results. Read here: https://www.exactsciences.com/newsroom/new-oncotype-dx-data-asco2020

Kent Nastiuk, MD of Roswell Park @RoswellPark discusses prostate tumor-derived GDF11 accelerates androgen deprivation therapy–induced sarcopenia. Read here: https://insight.jci.org/articles/view/127018?utm_source=Cision&utm_medium=Email&utm_term=Apr-20%60&utm_content=cancer%2c+melanoma%2c+prostate%2c+pancreatic%2c+rectal%2c+treatment%2c+studies%2c+research

Kent Nastiuk, MD of Roswell Park @RoswellPark discusses prostate tumor-derived GDF11 accelerates androgen deprivation therapy–induced sarcopenia. Read here: https://insight.jci.org/articles/view/127018?utm_source=Cision&utm_medium=Email&utm_term=Apr-20%60&utm_content=cancer%2c+melanoma%2c+prostate%2c+pancreatic%2c+rectal%2c+treatment%2c+studies%2c+research

Philadelphia, PA (June 8, 2020) –  Oncoceutics announced today a Brown University award of $3.4 million that will be used to support a group of research teams for preclinical research, IND-enabling studies and a first-in-human clinical trial for Oncoceutics’ imipridone ONC212. As part of this award, Oncoceutics has received a $1M subaward to complete the IND-enabling studies for ONC212. ONC212 will be the third imipridone to enter clinical trials for oncology and is an agonist for the G protein-coupled receptor (GPCR) GPR132 and the mitochondrial protease ClpP, both novel targets that are highly expressed in cancer cells.The award goes to…

Jesus Berdeja, MD of Sarah Cannon Research Institute discusses the BCMA CAR-T therapy JNJ-4528 in pretreated patients with multiple myeloma. Read here: https://meetinglibrary.asco.org/record/186155/abstract

Jesus Berdeja, MD of Sarah Cannon Research Institute discusses the CAR-T therapy JNJ-4528 in pretreated patients with multiple myeloma. Read here: https://meetinglibrary.asco.org/record/186155/abstract

Nicholas Vogelzang, MD of Comprehensive Cancer Center @CCCNevada discusses the single arm, phase 2, TRITON2 clinical trial supported FDA approval of Rubraca in mCRPC

Mikkael Sekeres, MD @MikkaelSekeres of Cleveland Clinic @ClevelandClinic discusses the phase II study of pevonedistat + azacitidine vs. A in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia, or low-blast acute myelogenous leukemia presented at this year’s virtual ASCO.

Mikkael Sekeres, MD @MikkaelSekeres of Cleveland Clinic @ClevelandClinic discusses the phase II study of pevonedistat + azacitidine vs. A in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia, or low-blast acute myelogenous leukemia presented at this year’s virtual ASCO.

Jame Abraham, MD @jamecancerdoc of Cleveland Clinic @ClevelandClinic discusses at this year’s virtual ASCO the phase I open label dose escalation and expansion of SGN-LIV1A administered weekly in breast cancer.

Jame Abraham, MD @jamecancerdoc of Cleveland Clinic @ClevelandClinic discusses at this year’s virtual ASCO the phase I open label dose escalation and expansion of SGN-LIV1A administered weekly in breast cancer.

Jeffrey Skolnik, MD of INOVIO Pharmaceuticals @InovioPharma discusses INO-5401 in combination with PD-1 inhibitor libtayo (cemiplimab) demonstrates 85%of newly diagnosed glioblastoma patients are alive12 months following treatment. Read here: http://s23.q4cdn.com/479936946/files/doc_news/INOVIOs-INO-5401-in-Combination-with-PD-1-Inhibitor-Libtayo-cemiplimab-Demonstrates-85-of-Newly-Diagnosed-Glioblastoma-Patients-Are-A-5VT78.pdf

Jeffrey Skolnik, MD of INOVIO Pharmaceuticals @InovioPharma discusses INO-5401 in combination with PD-1 inhibitor libtayo (cemiplimab) demonstrates 85%of newly diagnosed glioblastoma patients are alive12 months following treatment. Read here: http://s23.q4cdn.com/479936946/files/doc_news/INOVIOs-INO-5401-in-Combination-with-PD-1-Inhibitor-Libtayo-cemiplimab-Demonstrates-85-of-Newly-Diagnosed-Glioblastoma-Patients-Are-A-5VT78.pdf

Jeffrey Skolnik, MD of INOVIO Pharmaceuticals @InovioPharma discusses INO-5401 in combination with PD-1 inhibitor libtayo (cemiplimab) demonstrates 85% of newly diagnosed glioblastoma patients are alive 12 months following treatment. Read here: http://s23.q4cdn.com/479936946/files/doc_news/INOVIOs-INO-5401-in-Combination-with-PD-1-Inhibitor-Libtayo-cemiplimab-Demonstrates-85-of-Newly-Diagnosed-Glioblastoma-Patients-Are-A-5VT78.pdf

Elise De, MD of Massachussetts General Hospital @MassGeneralNews discusses the robotic assisted urethral diverticulectomy.

Elise De, MD of Massachussetts General Hospital @MassGeneralNews discusses the robotic assisted urethral diverticulectomy.

Salma Jabbour, MD @SalmaJabbour1 of Rutgers Cancer Institute of New Jersey @RutgersCancer discusses phase 2 Study of pembro plus platinum doublet chemotherapy and radiotherapy as first-line therapy for locally advanced NSCLC presented at this year’s virtual ASCO.

Salma Jabbour, MD @SalmaJabbour1 of Rutgers Cancer Institute of New Jersey @RutgersCancer discusses how patients tolerated this therapy? – Phase 2 Study of Pembro plus Platinum Doublet Chemotherapy and Radiotherapy as First-Line Therapy for Locally Advanced NSCLC.

Eva Domingo-Domenech, MD of Institut Català d’Oncologia – Hospitalet discusses ADCETRIS for Treatment of Adult Patients with Previously Untreated sALCL: Why are targeted therapies important in treating sALCL?

Eva Domingo-Domenech, MD of Institut Català d’Oncologia – Hospitalet discusses ADCETRIS for Treatment of Adult Patients with Previously Untreated sALCL: How ADCETRIS may impact the existing sALCL treatment landscape?

Eva Domingo-Domenech, MD of Institut Català d’Oncologia – Hospitalet discusses ADCETRIS for Treatment of Adult Patients with Previously Untreated sALCL: What study supported the approval of ADCETRIS for the treatment of adult patients with previously untreated sALCL?

Charles Rudin, MD @charlesrudin of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses KEYNOTE-604: pembrolizumab versus placebo plus etoposide and platnium as a first-line therapy in SCLC.

Charles Rudin, MD @charlesrudin of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses KEYNOTE-604: pembrolizumab versus placebo plus etoposide and platnium as a first-line therapy in SCLC.

John Kuruvilla, MD of Cleveland Clinic @ClevelandClinic discusses KEYNOTE-204: a randomized, open-label, phase III study of pembrolizumab vs. brentuximab vedotin in relapsed or refractory classic hodgkin lymphoma (R/R cHL)

John Kuruvilla, MD of Cleveland Clinic @ClevelandClinic discusses KEYNOTE-204: a randomized, open-label, phase III study of pembrolizumab vs. brentuximab vedotin in relapsed or refractory classic hodgkin lymphoma (R/R cHL)

John Kuruvilla, MD of Cleveland Clinic @ClevelandClinic discusses KEYNOTE-204: a randomized, open-label, phase III study of pembrolizumab vs. brentuximab vedotin in relapsed or refractory classic hodgkin lymphoma (R/R cHL)

Suneel Kamath, MD @SKamath_MD of Cleveland Clinic @ClevelandClinic discusses the effect of shorter time to treatment on survival in rural patients with breast cancer.

Suneel Kamath, MD @SKamath_MD of Cleveland Clinic @ClevelandClinic discusses the effect of shorter time to treatment on survival in rural patients with breast cancer.

Suneel Kamath, MD @SKamath_MD of Cleveland Clinic @ClevelandClinic discusses the effect of shorter time to treatment on survival in rural patients with breast cancer.

Moshe Ornstein, MD @MosheOrnsteinMD of Cleveland Clinic @ClevelandClinic discusses a phase Ib trial of neoadjuvant/adjuvant durvalumab +/- tremelimumab in locally advanced renal cell carcinoma (RCC) at this year’s virtual ASCO 2020.

Moshe Ornstein, MD @MosheOrnsteinMD of Cleveland Clinic @ClevelandClinic discusses a phase Ib trial of neoadjuvant/adjuvant durvalumab +/- tremelimumab in locally advanced renal cell carcinoma (RCC) at this year’s virtual ASCO 2020.

Philadelphia, PA (May 28, 2020) – Oncoceutics, Inc. announced that it and its collaborators will present several abstracts at the virtual 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) from Friday, May 29th to Tuesday, June 2nd that highlight the clinical safety and efficacy of ONC201 across a number of clinical trials, age groups and tumor types, including H3 K27M-mutant diffuse midline glioma. Additionally, a dedicated abstract will present the rationale and design of the first-in-human clinical trial for ONC206, the company’s second molecule of its portfolio of imipridones to enter clinical development.“The data presented at ASCO…

Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC San Francisco @UCSFMedicine discusses the new insights that links cell division to cancer. ___________ To replace aging and worn cells, the body primarily uses a process called mitosis, in which one cell divides into two. When a cell is ready to divide, it duplicates its DNA so a complete copy is available for each of the daughter cells. In this process, the DNA pieces, or chromosomes, must be precisely apportioned into the daughter cells. If one cell has an incomplete…

Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC San Francisco @UCSFMedicine discusses the new insights that links cell division to cancer. ___________ To replace aging and worn cells, the body primarily uses a process called mitosis, in which one cell divides into two. When a cell is ready to divide, it duplicates its DNA so a complete copy is available for each of the daughter cells. In this process, the DNA pieces, or chromosomes, must be precisely apportioned into the daughter cells. If one cell has an incomplete…

Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC San Francisco @UCSFMedicine discusses the new insights that links cell division to cancer. ___________ To replace aging and worn cells, the body primarily uses a process called mitosis, in which one cell divides into two. When a cell is ready to divide, it duplicates its DNA so a complete copy is available for each of the daughter cells. In this process, the DNA pieces, or chromosomes, must be precisely apportioned into the daughter cells. If one cell has an incomplete…

Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC San Francisco @UCSFMedicine discusses the new insights that links cell division to cancer. ___________ To replace aging and worn cells, the body primarily uses a process called mitosis, in which one cell divides into two. When a cell is ready to divide, it duplicates its DNA so a complete copy is available for each of the daughter cells. In this process, the DNA pieces, or chromosomes, must be precisely apportioned into the daughter cells. If one cell has an incomplete…

Fumito Ito, MD, PhD of Roswell Park @RoswellPark discusses CX3CR1–CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment. Read here: https://insight.jci.org/articles/view/133920?utm_source=Cision&utm_medium=Email&utm_term=Apr-20%60&utm_content=cancer%2c+melanoma%2c+prostate%2c+pancreatic%2c+rectal%2c+treatment%2c+studies%2c+research

Tannishtha Reya, PhD of UCSD @UCSDHealth discusses using genome-wide CRISPR technology to find leukemia’s vulnerabilities. … A team of researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukemia, a type of cancer that remains difficult to treat and is marked by frequent relapse. “We used CRISPR technology to carry out a genome-wide screen in leukemia cells to block thousands of genes at once. This is an extremely powerful tool that allowed us to identify a multitude of genes that fuel leukemia growth and…

Tannishtha Reya, PhD of UCSD @UCSDHealth discusses using genome-wide CRISPR technology to find leukemia’s vulnerabilities. _____________ A team of researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukemia, a type of cancer that remains difficult to treat and is marked by frequent relapse. “We used CRISPR technology to carry out a genome-wide screen in leukemia cells to block thousands of genes at once. This is an extremely powerful tool that allowed us to identify a multitude of genes that fuel leukemia growth and…

Heather Losey, PhD of Alkermes discusses ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. Read here: https://jitc.bmj.com/content/8/1/e000673

Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1 inhibitor ivosidenib and safety activity in patients with chondrosarcoma.

Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1 inhibitor ivosidenib and safety activity in patients with chondrosarcoma.

Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1 inhibitor ivosidenib and safety activity in patients with chondrosarcoma.

Philadelphia, PA (May 19, 2020) – Oncoceutics, Inc. announced that the latest research findings with ONC201 and its novel class of imipridones will be presented at the 2020 annual meeting of the American Association of Cancer Research (AACR) on June 22-24, 2020. The research presented at AACR highlights the antitumor and cancer prevention activity of ONC201 in tumor types with dysregulation of its two binding targets DRD2 and ClpP: H3 K27M-mutant diffuse midline glioma, endometrial cancer, medullary thyroid cancer, small cell lung cancer, and colon cancer. The presentations further highlight novel ONC201 biomarkers that help to further inform the clinical efficacy…

Seth Lerner, MD of Baylor College of Medicine @bcmhouston discusses the innovative approach option for treating upper tract urothelial cancer. ______________ Treatment of low-grade upper tract urothelial cancer usually involves radical surgery to remove the kidney and ureter, highlighting the need for improved treatments. An international team led by researchers at Baylor College of Medicine reports in the journal The Lancet Oncology that an innovative form of local chemotherapy using a mitomycin-containing reverse thermal gel offers a kidney-sparing treatment option for this rare cancer affecting 6,000 to 8,000 new patients in the United States every year. “Urothelial cancer refers to a cancer…

Seth Lerner, MD of Baylor College of Medicine @bcmhouston discusses the innovative approach option for treating upper tract urothelial cancer. ______________ Treatment of low-grade upper tract urothelial cancer usually involves radical surgery to remove the kidney and ureter, highlighting the need for improved treatments. An international team led by researchers at Baylor College of Medicine reports in the journal The Lancet Oncology that an innovative form of local chemotherapy using a mitomycin-containing reverse thermal gel offers a kidney-sparing treatment option for this rare cancer affecting 6,000 to 8,000 new patients in the United States every year. “Urothelial cancer refers to a cancer…

Seth Lerner, MD of Baylor College of Medicine @bcmhouston discusses the innovative approach option for treating upper tract urothelial cancer. ______________ Treatment of low-grade upper tract urothelial cancer usually involves radical surgery to remove the kidney and ureter, highlighting the need for improved treatments. An international team led by researchers at Baylor College of Medicine reports in the journal The Lancet Oncology that an innovative form of local chemotherapy using a mitomycin-containing reverse thermal gel offers a kidney-sparing treatment option for this rare cancer affecting 6,000 to 8,000 new patients in the United States every year. “Urothelial cancer refers to a cancer…

Elliot Norry, MD of Adaptimmune Therapeutics discusses the SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell liposarcoma (MRCLS). Adaptimmune’s ADP-A2M4 was granted ODD by the FDA late last year for soft tissue sarcomas and Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of synovial sarcoma. Read here: https://www.globenewswire.com/news-release/2020/04/28/2023245/0/en/Positive-Opinion-for-Orphan-Drug-Designation-for-ADP-A2M4-in-the-European-Union-for-the-Treatment-of-Soft-Tissue-Sarcoma-from-EMA-Committee-of-Orphan-Medicinal-Products.html

Elliot Norry, MD of Adaptimmune Therapeutics discusses the SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell liposarcoma (MRCLS). Adaptimmune’s ADP-A2M4 was granted ODD by the FDA late last year for soft tissue sarcomas and Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of synovial sarcoma. Read here: https://www.globenewswire.com/news-release/2020/04/28/2023245/0/en/Positive-Opinion-for-Orphan-Drug-Designation-for-ADP-A2M4-in-the-European-Union-for-the-Treatment-of-Soft-Tissue-Sarcoma-from-EMA-Committee-of-Orphan-Medicinal-Products.html  

Elliot Norry, MD of Adaptimmune Therapeutics discusses the SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell liposarcoma (MRCLS). Adaptimmune’s ADP-A2M4 was granted ODD by the FDA late last year for soft tissue sarcomas and Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of synovial sarcoma. Read here: https://www.globenewswire.com/news-release/2020/04/28/2023245/0/en/Positive-Opinion-for-Orphan-Drug-Designation-for-ADP-A2M4-in-the-European-Union-for-the-Treatment-of-Soft-Tissue-Sarcoma-from-EMA-Committee-of-Orphan-Medicinal-Products.html

Charis Eng, MD, PhD @charisengmdphd of Cleveland Clinic @clevelandclinic discusses the germline genomic profiles of children and young adults with solid tumors.

Charis Eng, MD, PhD @charisengmdphd of Cleveland Clinic @clevelandclinic discusses the germline genomic profiles of children and young adults with solid tumors.

Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to be presented at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I. The AhR receptor is expressed in many different immune cells and is considered to play an important role in immuno-suppression within the tumor microenvironment. An AhR inhibitor such as BAY 2416964 is thought to reactivate anti-tumor immune responses in a manner distinct from currently approved checkpoint inhibitors, and thus may provide a new approach for cancer immunotherapy. BAY 2416964 is currently investigated in a…

Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to be presented at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I. The AhR receptor is expressed in many different immune cells and is considered to play an important role in immuno-suppression within the tumor microenvironment. An AhR inhibitor such as BAY 2416964 is thought to reactivate anti-tumor immune responses in a manner distinct from currently approved checkpoint inhibitors, and thus may provide a new approach for cancer immunotherapy. BAY 2416964 is currently investigated in a…

Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to be presented at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I. The AhR receptor is expressed in many different immune cells and is considered to play an important role in immuno-suppression within the tumor microenvironment. An AhR inhibitor such as BAY 2416964 is thought to reactivate anti-tumor immune responses in a manner distinct from currently approved checkpoint inhibitors, and thus may provide a new approach for cancer immunotherapy. BAY 2416964 is currently investigated in a…

Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast cancer. Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy™ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for relapsed or refractory metastatic TNBC and is also the first FDA-approved anti-Trop-2 ADC.1…

Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast cancer. Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvyâ„¢ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for relapsed or refractory metastatic TNBC and is also the first FDA-approved anti-Trop-2 ADC.1…

Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast cancer. Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvyâ„¢ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for relapsed or refractory metastatic TNBC and is also the first FDA-approved anti-Trop-2 ADC.1…

Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast cancer. Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvyâ„¢ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for relapsed or refractory metastatic TNBC and is also the first FDA-approved anti-Trop-2 ADC.1…

Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast cancer. Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvyâ„¢ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for relapsed or refractory metastatic TNBC and is also the first FDA-approved anti-Trop-2 ADC.1…

Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast cancer. Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvyâ„¢ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for relapsed or refractory metastatic TNBC and is also the first FDA-approved anti-Trop-2 ADC.1…

David Hong, MD of MD Anderson Cancer Center @MDAndersonNews discusses at this year’s virtual AACR the efficacy and safety of larotrectinib in patients with cancer and NTRK gene fusions or other alterations.

Eyal Lebel, MD of Princess Margaret Cancer Centre @pmcancercentre discusses the rare recurrence of cutaneous anaplastic large cell lymphoma. Read here: https://ascopubs.org/doi/full/10.1200/JOP.19.00581

Sai-Hong Ignatius Ou, MD PhD Health Science Clinical ProfessorChao Family Comprehensive Cancer Center University of California Irvine School of Medicine discusses these topics. NSCLC treatment options (circa February 2020 updated May 2020)Targeted therapy (FDA Approved indication)EGFR classical mutationsEGFR uncommon mutationsALK fusionROS1 fusionBRAF V600EMETex14+ NSCLC (Approved May 6, 2020)RET fusion (Approved May 8, 2020)Immunotherapy (FDA approved)Chemotherapy + IO for first-line treatment of Non-Sq NSCLC, Sq NSCLC, and SCLC. (PD-L1 expression agnostic)Single agent second line (PD-L1 expression agnostic)Chemotherapy (FDA approved)Chemo + anti-angiogenesis mAb (non-Sq NSCLC)Chemo + anti EGFR mAb (Sq NSCLC)Single agent + anti-angiogenesis mAb Sponsors: AbbVie  AMAG AstraZeneca  Bayer  BeiGene  Clovis…

David Hong, MD of MD Anderson Cancer Center @MDAndersonNews discusses at this year’s virtual AACR the efficacy and safety of larotrectinib in patients with cancer and NTRK gene fusions or other alterations.

David Hong, MD of MD Anderson Cancer Center @MDAndersonNews discusses at this year’s virtual AACR the efficacy and safety of larotrectinib in patients with cancer and NTRK gene fusions or other alterations.

Richard Penson, MD of Massachusetts General Hospital @MassGeneralNews discusses a randomized phase III of olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3). Read here: https://ascopubs.org/doi/full/10.1200/JCO.19.02745

Richard Penson, MD of Massachusetts General Hospital @MassGeneralNews discusses a randomized phase III of olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3). Read here: https://ascopubs.org/doi/full/10.1200/JCO.19.02745

Adilia Hormigo, MD of Mount Sinai Health System @MountSinaiNYC discusses the clinical study of the safety and tolerability of laser interstitial thermal therapy and avelumab for recurrent glioblastoma.

Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D discusses preclinical pharmacokinetic and metabolic characterization of the next generation oral SERD AZD9833. AZD9833 is a best in class profile, next generation oral selective estrogen receptor degrader (SERD) with an established pharmacokinetic profile in the clinic – specifically, AZD9833 is a full antagonist and complete degrader of estrogen receptor in all preclinical cell line models tested.

Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D discusses preclinical pharmacokinetic and metabolic characterization of the next generation oral SERD AZD9833. AZD9833 is a best in class profile, next generation oral selective estrogen receptor degrader (SERD) with an established pharmacokinetic profile in the clinic – specifically, AZD9833 is a full antagonist and complete degrader of estrogen receptor in all preclinical cell line models tested.

Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D discusses preclinical pharmacokinetic and metabolic characterization of the next generation oral SERD AZD9833. AZD9833 is a best in class profile, next generation oral selective estrogen receptor degrader (SERD) with an established pharmacokinetic profile in the clinic – specifically, AZD9833 is a full antagonist and complete degrader of estrogen receptor in all preclinical cell line models tested.

Yuman Fong, MD surgical oncologist at City of Hope @cityofhope discusses the phase 1a/1b, open-label first-in-human study of the safety, tolerability, and feasibility of gene-edited autologous NeoTCR-T cells (NeoTCR-P1) administered to patients with locally advanced or metastatic solid tumors.

Yuman Fong, MD surgical oncologist at City of Hope @cityofhope discusses the phase 1a/1b, open-label first-in-human study of the safety, tolerability, and feasibility of gene-edited autologous NeoTCR-T cells (NeoTCR-P1) administered to patients with locally advanced or metastatic solid tumors.

Udai Banerji, MD @udai_banerji of The Institute of Cancer Research and Jonathan Pachter, PhD of Verastem Oncology discuss the new opportunities and RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in KRAS mutant cancers. Read here: https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-preliminary-data-investigator

Philadelphia, PA (May 5, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates Brain Tumor Awareness Month this May and expresses its support for all those affected by brain tumors. Brain tumors remain one of the greatest current health challenges as there are limited treatment options for patients, and prognoses continue to be poor. “In commemorating this month, we recognize not only the patients currently battling brain cancer, but also the families of those patients, the clinicians and caregivers treating them, the survivors, the patients who have lost their lives, and the researchers working to defeat this disease,” said…

Eyal Lebel, MD of Princess Margaret Cancer Centre @pmcancercentre discusses the rare recurrence of cutaneous anaplastic large cell lymphoma. Read here: https://ascopubs.org/doi/full/10.1200/JOP.19.00581

Udai Banerji, MD @udai_banerji of The Institute of Cancer Research discusses the phase 1 study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in KRAS mutant cancers. Read here: https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-preliminary-data-investigator  

Udai Banerji, MD @udai_banerji of The Institute of Cancer Research discusses the phase 1 study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in KRAS mutant cancers. Read here: https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-preliminary-data-investigator

Rachael Brake @rachael_brake of Takeda @TakedaOncology discusses the therapy designation for mobocertinib (TAK-788) for the treatment of NSCLC patients with EGFR exon 20 insertion mutations

Rachael Brake @rachael_brake of Takeda @TakedaOncology discusses the therapy designation for mobocertinib (TAK-788) for the treatment of NSCLC patients with EGFR exon 20 insertion mutations

Rachael Brake @rachael_brake of Takeda @TakedaOncology discusses the therapy designation for mobocertinib (TAK-788) for the treatment of NSCLC patients with EGFR exon 20 insertion mutations __________ The Breakthrough Therapy Designation is based on the overall response rate (ORR) and the long-term benefit seen in patients who responded in a Phase 1/2 study evaluating the safety and efficacy of mobocertinib in patients with locally advanced or metastatic NSCLC whose tumors harbor EGFR exon 20 insertion mutations and have been previously treated with systemic chemotherapy. This signals a potential advancement in addressing the needs of patients for whom no targeted therapies exist…

Ecaterina Dumbrava, MD of MD Anderson Cancer Center @MDAndersonNews discusses the phase I trial of COM701 presented at the virtual AACR 2020. Read here: https://www.clinicaltrials.gov/ct2/show/NCT03667716?term=NCT+03667716&draw=2&rank=1  

Ecaterina Dumbrava, MD of MD Anderson Cancer Center @MDAndersonNews discusses the phase I trial of COM701 presented at the virtual AACR 2020. Read here: https://www.clinicaltrials.gov/ct2/show/NCT03667716?term=NCT+03667716&draw=2&rank=1  

Ecaterina Dumbrava, MD of MD Anderson Cancer Center @MDAndersonNews discusses the phase I trial of COM701 presented at the virtual AACR 2020. Read here: https://www.clinicaltrials.gov/ct2/show/NCT03667716?term=NCT+03667716&draw=2&rank=1

Enrique Soto, MD @EnriqueSoto8 of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán @incmnszmx discusses the importance of real world outcomes among older women with breast cancer treated with neoadjuvant chemotherapy. Read here: https://theoncologist.onlinelibrary.wiley.com/doi/10.1634/theoncologist.2019-0891

Enrique Soto, MD @EnriqueSoto8 of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán @incmnszmx discusses the real world outcomes among older women with breast cancer treated with neoadjuvant chemotherapy. What advantages can this type of study give us? Read here: https://theoncologist.onlinelibrary.wiley.com/doi/10.1634/theoncologist.2019-0891

Enrique Soto, MD @EnriqueSoto8 of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán @incmnszmx discusses the real world outcomes among older women with breast cancer treated with neoadjuvant chemotherapy. Read here: https://theoncologist.onlinelibrary.wiley.com/doi/10.1634/theoncologist.2019-0891

Himisha Beltran, MD of Dana Farber @DanaFarber discusses circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer and patients as they progress on treatment. Read here; https://www.jci.org/articles/view/131041  

Matthew Galsky, MD of Mount Sinai Health System @IcahnMountSinai @MountSinaiNYC discusses if switch maintenance immunotherapy is a standard base treatment for urothelial cancer yet. ___________ The study is the first to show that this approach to therapy, called switch maintenance immunotherapy, significantly slows the worsening of a type of bladder cancer called urothelial cancer. The randomized Phase 2 trial tested this treatment in 108 patients. “This trial, along with another recent study testing a similar approach, bolster the use of switch maintenance treatment, which will likely become a standard of care for metastatic urothelial cancer, a disease characterized by a…

Himisha Beltran, MD of Dana Farber @DanaFarber discusses circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. How do we identify a subgroup of patients? Read here: https://www.jci.org/articles/view/131041  

Matthew Galsky, MD of Mount Sinai Health System @IcahnMountSinai @MountSinaiNYC answers what is the role of a switch maintenance immune checkpoint blockade approach? What does this mean for standard practice? _____________ The study is the first to show that this approach to therapy, called switch maintenance immunotherapy, significantly slows the worsening of a type of bladder cancer called urothelial cancer. The randomized Phase 2 trial tested this treatment in 108 patients. “This trial, along with another recent study testing a similar approach, bolster the use of switch maintenance treatment, which will likely become a standard of care for metastatic urothelial…

Andrea Wang-Gillam, MD, PhD of Washington University School of Medicine @WUSTLmed answers if the phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer can be expanded. Presented at this year’s AACR Annual Meeting.

Himisha Beltran, MD of Dana Farber @DanaFarber discusses circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. Read here: https://www.jci.org/articles/view/131041  

Matthew Galsky, MD of Mount Sinai Health System @IcahnMountSinai @MountSinaiNYC discusses switch maintenance immunotherapy, significantly slows the worsening of a type of bladder cancer called urothelial cancer. _________ The study is the first to show that this approach to therapy, called switch maintenance immunotherapy, significantly slows the worsening of a type of bladder cancer called urothelial cancer. The randomized Phase 2 trial tested this treatment in 108 patients. “This trial, along with another recent study testing a similar approach, bolster the use of switch maintenance treatment, which will likely become a standard of care for metastatic urothelial cancer, a disease…

Andrea Wang-Gillam, MD, PhD of Washington University School of Medicine @WUSTLmed discusses the phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer presented at this year’s AACR Annual Meeting.

Rebecca Nagy of Guardant Health Inc. discusses women with metastatic hormone receptor-positive (HR+) breast cancer having experienced improved clinical outcomes with the recent introduction of alpelisib, a PIK3CA inhibitor. Read here: https://www.globenewswire.com/news-release/2020/04/09/2014287/0/en/Study-Shows-Guardant360-Test-Identifies-Predictors-of-Response-to-PIK3CA-Inhibitors-in-Women-with-HR-Metastatic-Breast-Cancer.html  

Michael Gnant, MD of University of Vienna @MedUni_Vienna discusses the impact of multigenomic assays in premenopausal patients and those with node-positive breast cancer. Read here: https://dailynews.ascopubs.org/do/10.1200/ADN.20.200006/full/?cid=DM4922&bid=42056373&

Rebecca Nagy of Guardant Health Inc. discusses women with metastatic hormone receptor-positive (HR+) breast cancer having experienced improved clinical outcomes with the recent introduction of alpelisib, a PIK3CA inhibitor. Read here: https://www.globenewswire.com/news-release/2020/04/09/2014287/0/en/Study-Shows-Guardant360-Test-Identifies-Predictors-of-Response-to-PIK3CA-Inhibitors-in-Women-with-HR-Metastatic-Breast-Cancer.html

Michael Gnant, MD of University of Vienna @MedUni_Vienna discusses using multigenomic assays in premenopausal patients and those with node-positive breast cancer. Read here: https://dailynews.ascopubs.org/do/10.1200/ADN.20.200006/full/?cid=DM4922&bid=42056373&

Michael Gnant, MD of University of Vienna @MedUni_Vienna discusses using multigenomic assays in premenopausal patients and those with node-positive breast cancer. Read here: https://dailynews.ascopubs.org/do/10.1200/ADN.20.200006/full/?cid=DM4922&bid=42056373&

Rebecca Nagy of Guardant Health Inc. discusses women with metastatic hormone receptor-positive (HR+) breast cancer having experienced improved clinical outcomes with the recent introduction of alpelisib, a PIK3CA inhibitor. Read here: https://www.globenewswire.com/news-release/2020/04/09/2014287/0/en/Study-Shows-Guardant360-Test-Identifies-Predictors-of-Response-to-PIK3CA-Inhibitors-in-Women-with-HR-Metastatic-Breast-Cancer.html

Brenda De Keersmaecker of eTheRNA Immunotherapies discusses a strong link between T cell activation and durable clinical benefit (DCB) in late stage melanoma patients following vaccination with TriMix and tumor associated antigen mRNA modified dendritic cells plus ipilimumab. __________ For four cycles, monocyte-derived dendritic cells electroporated with mRNA encoding CD70, CD40 ligand, and constitutively active TLR4 (TriMix), as well as TAAs tyrosinase, gp100, MAGE-A3, and MAGE-C2 were administered along with ipilimumab. A supplementary vaccine was provided for 18/39 patients prior to the first administration of ipilimumab. In previously collected peripheral mononuclear blood cells, which were available for 15 of the…

Laurie Schenkel of Ribon Therapeutics @RibonTx discusses a potent and selective PARP14 inhibitor decreases pro-tumor macrophage function and elicits inflammatory responses in tumor explants. __________ PARPs (poly-ADP-ribose polymerases) are a family of enzymes that regulate a wide variety of important cellular processes including cellular stress signaling pathways implicated in inflammation and cancer. PARP14 is a member of the monoPARP sub-family of PARPs, which catalyze transfer of a single ADP ribose unit (mono-ADP-ribosylation or MARylation) to their substrates, unlike their polyPARP counterparts which construct chains of ADP ribose units (poly-ADP-ribosylation or PARylation). PARP14 is an interferon-stimulated gene (ISG) that is overexpressed…

Melissa Vasbinder of Ribon Therapeutics @RibonTx discusses a first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways: is this going to affect clinicians and treatment today? ________________ PARP7 is a monoPARP that catalyzes the transfer of single units of ADP-ribose onto substrates to change their function (MARylation). PARP7 expression is increased by cellular stresses, including aromatic hydrocarbons and the PARP7 gene is amplified in cancers, especially in those of the upper aerodigestive tract. PARP7 has also been reported to negatively regulate the Type I interferon (IFN) response by interacting with TBK1 during viral infection. As part of…

Laurie Schenkel of Ribon Therapeutics @RibonTx discusses a potent and selective PARP14 inhibitor decreases pro-tumor macrophage function and elicits inflammatory responses in tumor explants. __________ PARPs (poly-ADP-ribose polymerases) are a family of enzymes that regulate a wide variety of important cellular processes including cellular stress signaling pathways implicated in inflammation and cancer. PARP14 is a member of the monoPARP sub-family of PARPs, which catalyze transfer of a single ADP ribose unit (mono-ADP-ribosylation or MARylation) to their substrates, unlike their polyPARP counterparts which construct chains of ADP ribose units (poly-ADP-ribosylation or PARylation). PARP14 is an interferon-stimulated gene (ISG) that is overexpressed…

Brenda De Keersmaecker of eTheRNA Immunotherapies discusses a strong link between T cell activation and durable clinical benefit (DCB) in late stage melanoma patients following vaccination with TriMix and tumor associated antigen mRNA modified dendritic cells plus ipilimumab. __________ For four cycles, monocyte-derived dendritic cells electroporated with mRNA encoding CD70, CD40 ligand, and constitutively active TLR4 (TriMix), as well as TAAs tyrosinase, gp100, MAGE-A3, and MAGE-C2 were administered along with ipilimumab. A supplementary vaccine was provided for 18/39 patients prior to the first administration of ipilimumab. In previously collected peripheral mononuclear blood cells, which were available for 15 of the…

Melissa Vasbinder of Ribon Therapeutics @RibonTx discusses a first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways. ________________ PARP7 is a monoPARP that catalyzes the transfer of single units of ADP-ribose onto substrates to change their function (MARylation). PARP7 expression is increased by cellular stresses, including aromatic hydrocarbons and the PARP7 gene is amplified in cancers, especially in those of the upper aerodigestive tract. PARP7 has also been reported to negatively regulate the Type I interferon (IFN) response by interacting with TBK1 during viral infection. As part of our drug discovery efforts to identify inhibitors of PARP7,…

Brenda De Keersmaecker of eTheRNA Immunotherapies discusses a strong link between T cell activation and durable clinical benefit (DCB) in late stage melanoma patients following vaccination with TriMix and tumor associated antigen mRNA modified dendritic cells plus ipilimumab. __________ For four cycles, monocyte-derived dendritic cells electroporated with mRNA encoding CD70, CD40 ligand, and constitutively active TLR4 (TriMix), as well as TAAs tyrosinase, gp100, MAGE-A3, and MAGE-C2 were administered along with ipilimumab. A supplementary vaccine was provided for 18/39 patients prior to the first administration of ipilimumab. In previously collected peripheral mononuclear blood cells, which were available for 15 of the…

Melissa Vasbinder of Ribon Therapeutics @RibonTx discusses a first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways. ________________ PARP7 is a monoPARP that catalyzes the transfer of single units of ADP-ribose onto substrates to change their function (MARylation). PARP7 expression is increased by cellular stresses, including aromatic hydrocarbons and the PARP7 gene is amplified in cancers, especially in those of the upper aerodigestive tract. PARP7 has also been reported to negatively regulate the Type I interferon (IFN) response by interacting with TBK1 during viral infection. As part of our drug discovery efforts to identify inhibitors of PARP7,…

Rumela Chakrabarti, PhD of Penn Medicine @PennMedicine explains how important it is to tailor treatment for triple-negative breast cancer patients. _____________ Immunotherapies have revolutionized care for people with multiple cancers. But when offered to those with triple-negative breast cancer (TNBC), an particularly aggressive type of the disease, fewer than 20 percent respond. “A big question in the field has been, Why are the rest not responding?” says Rumela Chakrabarti, an assistant professor at Penn’s School of Veterinary Medicine. Chakrabarti and the colleagues illuminate the nature of the molecules at play. We identified a signaling mechanism that could be used for…

Rumela Chakrabarti, PhD of Penn Medicine @PennMedicine answers how come interferon gamma is acting differently? _____________ Immunotherapies have revolutionized care for people with multiple cancers. But when offered to those with triple-negative breast cancer (TNBC), an particularly aggressive type of the disease, fewer than 20 percent respond. “A big question in the field has been, Why are the rest not responding?” says Rumela Chakrabarti, an assistant professor at Penn’s School of Veterinary Medicine. Chakrabarti and the colleagues illuminate the nature of the molecules at play. We identified a signaling mechanism that could be used for potential improved target therapies in…

Rumela Chakrabarti, PhD of Penn Medicine @PennMedicine discusses tailoring revolutionary treatment for triple-negative breast cancer. _____________ Immunotherapies have revolutionized care for people with multiple cancers. But when offered to those with triple-negative breast cancer (TNBC), an particularly aggressive type of the disease, fewer than 20 percent respond. “A big question in the field has been, Why are the rest not responding?” says Rumela Chakrabarti, an assistant professor at Penn’s School of Veterinary Medicine. Chakrabarti and the colleagues illuminate the nature of the molecules at play. We identified a signaling mechanism that could be used for potential improved target therapies in…

Paulo Rodriguez, PhD of Moffitt Cancer Center @MoffittNews explains immunosuppression in tumors overall in the study. ______________ An active immune system plays an important role in stopping the development of cancer by detecting and targeting the tumor cells for destruction. Some change in the immune system’s normal activities can lead to accelerated growth of tumors. Researchers at the Moffitt Cancer Center decided to find out how myeloid cells, a form of immune cell, may contribute to cancer progression. The Moffitt team explains how protein-signaling pathways associated with cellular stress processes turn myeloid cells into tumor-promoting players, and indicates that targeting…

Paulo Rodriguez, PhD of Moffitt Cancer Center @MoffittNews answers what the effects are in activation for identifying molecular pathways that control immunosuppression in tumors. ______________ An active immune system plays an important role in stopping the development of cancer by detecting and targeting the tumor cells for destruction. Some change in the immune system’s normal activities can lead to accelerated growth of tumors. Researchers at the Moffitt Cancer Center decided to find out how myeloid cells, a form of immune cell, may contribute to cancer progression. The Moffitt team explains how protein-signaling pathways associated with cellular stress processes turn myeloid…

Paulo Rodriguez, PhD of Moffitt Cancer Center @MoffittNews discusses identifying molecular pathways that control immunosuppression in tumors. ______________ An active immune system plays an important role in stopping the development of cancer by detecting and targeting the tumor cells for destruction. Some change in the immune system’s normal activities can lead to accelerated growth of tumors. Researchers at the Moffitt Cancer Center decided to find out how myeloid cells, a form of immune cell, may contribute to cancer progression. The Moffitt team explains how protein-signaling pathways associated with cellular stress processes turn myeloid cells into tumor-promoting players, and indicates that…

In this video series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have a candid discussion regarding cancer and Covid 19. In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients. In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic. Part 1 – Should…

In this video series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have a candid discussion regarding cancer and Covid 19. In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients. In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic. Part 1 – Should…

In this video series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have a candid discussion regarding cancer and Covid 19. In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients. In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic. Part 1 – Should…

In this video series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have a candid discussion regarding cancer and Covid 19. In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients. In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic. Part 1 – Should…

In April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy had a candid discussion regarding telemedicine in the time of the current pandemic. In this time of social distancing and limiting clinic exposure, the sudden need for telemedicine and web consults is perhaps changing the future of medicine on a faster pace than we have previously thought possible. In this three part series the doctors discuss a wide range of topics surrounding the use of telemedicine and potential challenges for providers and patients alike. Does this new process create new helpful tools?…

In April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy had a candid discussion regarding telemedicine in the time of the current pandemic. In this time of social distancing and limiting clinic exposure, the sudden need for telemedicine and web consults is perhaps changing the future of medicine on a faster pace than we have previously thought possible. In this three part series the doctors discuss a wide range of topics surrounding the use of telemedicine and potential challenges for providers and patients alike. Does this new process create new helpful tools?…

In April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy had a candid discussion regarding telemedicine in the time of the current pandemic. In this time of social distancing and limiting clinic exposure, the sudden need for telemedicine and web consults is perhaps changing the future of medicine on a faster pace than we have previously thought possible. In this three part series the doctors discuss a wide range of topics surrounding the use of telemedicine and potential challenges for providers and patients alike. Does this new process create new helpful tools?…

In this video from our Cancer Basics series, Narjust Duma, MD, Assistant Professor and Thoracic Oncologist with the University of Wisconsin Carbone Cancer Center interviews Dr. Grace Blitzer, Radiation Oncology Resident with the Department of Human Oncology at the University of Wisconsin School of Medicine and Public Health. Dr. Blitzer shares with us a great description of what a CT Simulation Scan for Radiation Therapy is, how it is used, and why it is important for receiving radiation therapy. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center discusses COVID 19 and how it affects the community. The second video in this 2 part series, presented in Spanish for the Latino community, covers information relating to the following topics: What is coronavirus? What are the common symptoms? How is it contracted, and how can it be prevented? Who is at risk, and are people with cancer at higher risk? Does the risk of exposure change my treatment for cancer? What happens if I get coronavirus and have cancer? I hear about treatments:…

Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center discusses COVID 19 and how it affects the community. This 2 part series, presented in Spanish for the Latino community, covers information relating to the following topics: What is coronavirus? What are the common symptoms? How is it contracted, and how can it be prevented? Who is at risk, and are people with cancer at higher risk? Does the risk of exposure change my treatment for cancer? What happens if I get coronavirus and have cancer? I hear about treatments: are these now established…

In partnership with Clinical Care Options, GRACE President Jack West, MD provides information regarding immunotherapy for advanced NSCLC, and discussing goals and treatments with your health care providers.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center interviews Julia Maues, breast cancer patient and advocate, and founder of https://www.itsnot.pink/.In this interview, Dr. Duma interviews Julia about her journey as a cancer patient and becoming an advocate. This interview is done in Portuguese, for our global community. For more information (in english) about Julia’s journey, please visit https://www.itsnot.pink/my-story.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center interviews Juanita Segura, lung cancer patient and advocate. In this series Juanita shares her inspiring story from diagnosis to today, showing how her positivity and optimism powers her through. In this third and final video Juanita shares with us her message – she is still living.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center interviews Juanita Segura, lung cancer patient and advocate. In this series Juanita shares her inspiring story from diagnosis to today, showing how her positivity and optimism powers her through. In this second video Juanita discusses her treatment journey.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center interviews Juanita Segura, lung cancer patient and advocate. In this series Juanita shares her inspiring story from diagnosis to today, showing how her positivity and optimism powers her through.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.In this series, the doctors discuss a series of cases related to EGFR Mutations. In an EGFR mutation with MET amplification, what are treatment decisions and what is the importance of the level of MET amplification?For more, please visit http://cancerGRACE.org/. To join…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.In this series, the doctors discuss a series of cases related to EGFR Mutations. For EGFR mutations treated with Tagrisso, and with progression while on treatment, what is the role of repeat biopsy?For more, please visit http://cancerGRACE.org/. To join the conversation, visit…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.In this series, the doctors discuss a series of cases related to EGFR Mutations. For EGFR mutations and the FLAURA trial, is there a difference in data based on demographics and how can that effect treatment decisions?For more, please visit http://cancerGRACE.org/. To…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach. Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center. Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR mutations, patient progression and next steps. Is there a place for chemo and the inclusion of immunotherapy? Where does immunotherapy fit in to the mix? For…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach. Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center. Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutation with high PDL-1 – does immunotherapy have a role in treatment? For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.In this series, the doctors discuss a series of cases related to EGFR mutations and what is the recommended treatment for common EGFR mutations.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach. Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center. Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations – is there a place for chemotherapy and an EGFR inhibitor concurrently or sequentially in treatment decisions? For more, please visit http://cancerGRACE.org/. To join the…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach. Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center. Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations – is there a place for chemotherapy and an EGFR inhibitor concurrently or sequentially in treatment decisions? For more, please visit http://cancerGRACE.org/. To join the…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.In this series, the doctors discuss a series of cases related to an EGFR mutation. In this video, the discussion is regarding uncommon EXON 20 mutation, suggested treatments, targeted therapy and clinical trials.For more, please visit http://cancerGRACE.org/. To join the conversation, visit…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.The doctors discuss a series of cases related to a diagnosis of NSCLC. In this video, the discussion is regarding a patient with a HER2 mutation, what is the clinical significance, and how does a positive HER2 mutation effect treatment decisions?For more, please visit http://cancerGRACE.org/. To join…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center. The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is regarding a patient with ALK positive and high PDL-1. What is the first line treatment for potentially competing targets? For more, please visit…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, they discuss progression after success on Alk inhibitors, and if there is a role for combination therapies like chemo/radiation and immunotherapy.For more, please visit http://cancerGRACE.org/. To join the conversation,…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center. The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is regarding progression after success on an ALK inhibitor. Do you continue the ALK inhibitor when transitioning to a chemo based treatment? For more,…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center. The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, they discuss developing resistance to Alk inhibitors, treatment approaches and biopsies, and what are the next steps. For more, please visit http://cancerGRACE.org/. To join the conversation,…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center. The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, they discuss developing resistance to Alk inhibitors, treatment approaches and biopsies, and what are the next steps. For more, please visit http://cancerGRACE.org/. To join the conversation,…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center. The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is regarding a patient with ALK positive asymptomatic brain metastases. Is the standard approach of focal radiation before beginning ALK inhibitor appropriate, or do…

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center. The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is surrounding what the approach for first line treatment would be for a patient with good performance status, lung adenocarcinoma, metastatic disease and adrenal…

Terapias para el Cancer: Conocimientos Basicos (Cancer Therapy – Basics) ¿Que es oncologia geriátrica? What is Geriatric Oncology? Narjust (N.J.) Duma, MD, Assistant Professor And Thoracic Oncologist with the University of Wisconsin Carbone Cancer Center Provides us with more information for our Latino community. In this video Dr. Duma speaks with Enrique Soto Pérez de Celis, MD, a Medical Oncologist / Oncólogo Médico with the Department of Geriatrics / Oncología Geriátrica at the Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico. In this spanish language video Dr. Duma and Dr. Soto discuss geriatric oncology. For more,…

Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis. Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma,…

Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis. Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma,…

Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis. Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma,…

Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis. Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma,…

Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis. Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma,…

Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis. Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma,…

Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis. Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma,…

Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Gail J. Roboz and the symposium faculty discuss a series of cases that demonstrate the use of MRD testing in the treatment of hematologic malignancies. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Ajay Chari discusses the role of MRD in the treatment of multiple myeloma. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Steven E. Coutre discusses the role of MRD testing in the treatment of chronic lymphocytic leukemia (CLL). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Gail J. Roboz discusses the role of minimal residual disease (MRD) testing in the treatment of acute myeloid leukemia (AML). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Aaron C. Logan discusses the latest treatment guidelines for acute lymphocytic leukemia (ALL). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Prashant Kapoor provides an overview of the game-changing potential that MRD has in the treatment of hematologic malignancies. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/19-gdugi-5 In this webcast from the ‘Making Progress in Advanced Hepatocellular Carcinoma with Targeted Agents: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Tanios S. Bekaii-Saab presents a case of advanced HCC that elucidates the role of immunotherapy. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/19-gdugi-5 In this webcast from the ‘Making Progress in Advanced Hepatocellular Carcinoma with Targeted Agents: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Ghassan Abou-Alfa discusses novel agents and therapeutic targets for the treatment of biliary cancer. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/19-gdugi-5 In this webcast from the ‘Making Progress in Advanced Hepatocellular Carcinoma with Targeted Agents: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Pashtoon Kasi discusses best practices for the management of adverse events associated with the treatment of HCC. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-gdugi-3 In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment Tolerability’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Michael A. Choti argues in favor of utilizing adjuvant FOLFIRINOX for the treatment of pancreatic cancer. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-gdu… In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment Tolerability’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Jordan D. Berlin argues in favor of utilizing preoperative chemo/chemoradiotherapy for the treatment of pancreatic cancer. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/19-gdugi-3 In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment Tolerability’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Christopher L. Hallemeier argues in favor of utilizing stereotactic body radiation therapy (SBRT) for the preoperative treatment of borderline resectable pancreatic cancer. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/19-gdugi-3 In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment Tolerability’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Christopher Crane argues in favor of utilizing conventional radiation therapy for the preoperative treatment of borderline resectable pancreatic cancer. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/19-gdugi-4 In this webcast from the ‘Exploring the Evolving Role of Immunotherapy in Advanced Hepatocellular Carcinoma: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Tanios S. Bekaii-Saab presents a case of hepatocellular carcinoma (HCC) that elucidates the role of imunotherapy. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/19-gdugi-4 In this webcast from the ‘Exploring the Evolving Role of Immunotherapy in Advanced Hepatocellular Carcinoma: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Pashtoon Kasi discusses the best practices for the management of adverse events associated with therapies utilized in the treatment of hepatocellular carcinoma (HCC). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-gdugi-1 In this webcast from the ‘Metastatic Colorectal Cancer: An individualized Approach to Optimal Treatment Selection and Adverse Events Management’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, the session panel discuss cases elucidating the finer points of individualized treatment selection and therapeutic sequencing in next-line metastatic colorectal cancer. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-cpc-101-7 This webcast features a presentation by Dr. Gary H. Lyman that examines the potential benefits of incorporating biosimilars into oncology clinical pathways. © 2019 NACCME, an HMP Company

Earn CME: https://www.naccme.com/program/19-cpc-101-6 This webcast features a presentation by Dr. Alexander B. Olawaiye that discusses the integration of PARP inhibitors into evidence-based ovarian cancer clinical pathways based on discrete PARP factors, latest clinical data, and guideline recommendations for the treatment of ovarian cancer. © 2019 NACCME, an HMP Company

Earn CME: https://www.naccme.com/program/19-cpc-101-5 This webcast features a presentation by Dr. Atish D. Choudhury that examines the latest clinical safety and efficacy data surrounding next-generation antiandrogen agents for initial treatment of localized hormone-sensitive prostate cancer (HSPC). © 2019 NACCME, an HMP Company

Earn CME: https://www.naccme.com/program/19-cpc-101-4 This webcast features a presentation by Dr. Amir T. Fathi on best practices for the integration of recent therapeutic advances, resource utilization data, and current guidance into AML clinical pathways discussions. © 2019 NACCME, an HMP Company

Earn CME: https://www.naccme.com/program/19-cpc-101-3 This webcast features a presentation by Dr. David Jackman discusses the latest efficacy and safety data, indications, and cost utility of novel therapies into optimal selection and non-small cell lung cancer (NSCLC) pathway placement strategies. © 2019 NACCME, an HMP Company

Earn CME: https://www.naccme.com/program/19-cpc-101-2 This webcast features a presentation by Dr. Gabriella Hobbs that examines the most recent evidence-based guidelines to optimize individualized tyrosine kinase inhibitor (TKI) selection for chronic myeloid leukemia (CML) patients based on disease phase, treatment history, genetic mutation profile, and comorbidities, © 2019 NACCME, an HMP Company

Earn CME: https://www.naccme.com/program/19-cpc-101-1 This webcast features a presentation by Dr. Nicole M. Kuderer that examines pharmacological profiles of novel and emerging metastatic breast cancer (MBC) agents, including their indications, potential place in therapy, and recent clinical data. © 2019 NACCME, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-15 In this webcast from the ‘New and Emerging Agents in MCL’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Michael E. Williams discusses novel agents for the treatment of mantle cell lymphoma (MCL). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-14 In this webcast from the ‘Revolutionizing the R/R DLBCL Treatment Paradigm: Innovative, Strategic & Targeted Approaches’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. John P. Leonard discusses the current state of upfront management of diffuse large b-cell lymphoma (DLBCL). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-13 In this webcast from the ‘Treatment for Marginal Zone Lymphoma: Should it be Different from FL?’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Thomas M. Habermann discusses the treatment of marginal zone lymphoma (MZL). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-13 In this webcast from the ‘Treatment for Marginal Zone Lymphoma: Should it be Different from FL?’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Thomas M. Habermann discusses whether treatment of marginal zone lymphoma (MZL) should be different than that of follicular lymphoma. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-11 In this webcast from the ‘Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K Inhibitors’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Martin, Casulo, Fischer, Cheson, and Haberman discuss the treatment of lymphoma on a panel discussion. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-11 In this webcast from the ‘Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K Inhibitors’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Bruce D. Cheson and Richard I. Fisher debate whether chemotherapy still has a major role in the treatment of follicular lymphoma. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-11 In this webcast from the ‘Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K Inhibitors’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Peter Martin and Carla Casulo debate whether patients with follicular lymphoma should be treated immediately. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-10 In this webcast from the ‘New and Emerging Agents in Hairy Cell Leukemia (HCL)’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Barrientos and Park discuss their presentations and answer questions on the treatment of hairy cell leukemia (HCL). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-10 In this webcast from the ‘New and Emerging Agents in Hairy Cell Leukemia (HCL)’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Jae Park discusses new and emerging treatment options for patients with hairy cell leukemia (HCL). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-10 In this webcast from the ‘New and Emerging Agents in Hairy Cell Leukemia (HCL)’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Jacqueline C. Barrientos discusses the efficacy and safety of current treatment options for hairy cell leukemia (HCL). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-09 In this webcast from the ‘Understanding Waldenström’s Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and Emerging Therapies’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Steven B. Treon discusses treatment options for a a series of cases of Waldenström’s Macroglobulinemia. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-09 In this webcast from the ‘Understanding Waldenström’s Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and Emerging Therapies’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Steven B. Treon discusses his approach to the treatment of Waldenström’s Macroglobulinemia. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. James R. Berenson, Adam D. Cohen, Deepu Madduri, and Sham Mailankody discuss the current and future state of CAR-T therapy for myeloma patients. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Adam D. Cohen discusses next-generation CAR-T produces and strategies. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Sham Mailankody discusses responses to CAR-T therapy in patients with myeloma. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. James R. Berenson discusses the role of b-cell maturation antigen (BCMA) in predicting outcomes and monitoring patients with multiple myeloma or chronic lymphocytic leukemia. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-03 In this webcast from the ‘Minimal Residual Disease in Hematologic Malignancies Testing Considerations and Challenges’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Raphael Fonseca discusses use the of MRD testing, single cell RNA sequencing, and cell free DNA testing in the treatment of hematologic malignancies. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-03 In this webcast from the ‘Minimal Residual Disease in Hematologic Malignancies Testing Considerations and Challenges’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Gail J. Roboz discusses the use of MRD as a target for the treatment of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-02 In this webcast from the ‘Advances in TKI Therapy for CML: Navigating the Future Treatment Landscape’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Desai, Lee, Roboz, and van Besien discuss their presentations and answer questions. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-02 In this webcast from the ‘Advances in TKI Therapy for CML: Navigating the Future Treatment Landscape’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Pinkal Desai and Sangmin Lee debate whether patients in major molecular remission © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-02 In this webcast from the ‘Advances in TKI Therapy for CML: Navigating the Future Treatment Landscape’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Sangmin Lee discusses current approaches to optimizing care. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Desai, Lee, and Roboz elaborate on their presentations from the symposium. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Pinkal Desai and Sangmin Lee debate whether venetoclax + azacitidine/decitabine/LDAC should be the new standard of care for acute myeloid leukemia (AML) patients greater than equal to 60 years of age. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Gail J. Roboz discusses novel targeted therapies for the treatment of newly diagnosed acute myeloid leukemia (AML). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Gail J. Roboz discusses novel therapies for the treatment of newly diagnosed acute myeloid leukemia (AML). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-04 In this webcast from the ‘Recent Advances in Acute Leukemia Management’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Pinkal Desai discusses therapeutic strategies for the difficult-to-treat patient with acute lymphocytic leukemia (ALL). © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/19-lm-05 In this webcast from the ‘Multiple Myeloma: Treatment Challenges and Updates’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Deepu Madduri discusses best practices for dealing with adverse events and toxicities related to CAR-T therapy.

Jakob Lindberg, CEO of Oncopeptides @oncopeptides explains the alkylating properties in the treatment of relapsed/refractory multple myeloma. ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.   Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background on this news, Oncopeptides hosted a webcast today to provide an update on the final study…

Zachary Frosch, MD of Penn Medicine @PennMedicine explains that more prospective data is needed to validate stratification of molecular risk in aggressive b-cell lymphoma. Diffuse large B-cell lymphoma (DLBCL) has become increasingly evident in recent years as not a single pathological entity. Wide-ranging diagnostic techniques such as immunohistochemical staining and fluorescence in situ hybridization (FISH) have helped to sub-categorize DLBCLs by their pathological characteristics and classify those associated with lower likelihood of cure with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) rituximab after typical first-line cure. This recognition has prompted expanded use of diagnostic testing to classify patients with high-risk severe…

Zachary Frosch, MD of Penn Medicine @PennMedicine answers how stratification of molecular risk in aggressive b-cell lymphoma is validated. Diffuse large B-cell lymphoma (DLBCL) has become increasingly evident in recent years as not a single pathological entity. Wide-ranging diagnostic techniques such as immunohistochemical staining and fluorescence in situ hybridization (FISH) have helped to sub-categorize DLBCLs by their pathological characteristics and classify those associated with lower likelihood of cure with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) rituximab after typical first-line cure. This recognition has prompted expanded use of diagnostic testing to classify patients with high-risk severe lymphoma, the findings of which…

Zachary Frosch, MD of Penn Medicine @PennMedicine discusses stratification of molecular risk in aggressive b-cell lymphoma. Diffuse large B-cell lymphoma (DLBCL) has become increasingly evident in recent years as not a single pathological entity. Wide-ranging diagnostic techniques such as immunohistochemical staining and fluorescence in situ hybridization (FISH) have helped to sub-categorize DLBCLs by their pathological characteristics and classify those associated with lower likelihood of cure with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) rituximab after typical first-line cure. This recognition has prompted expanded use of diagnostic testing to classify patients with high-risk severe lymphoma, the findings of which have often led…

According to GlobalData, a leading data and analytics firm, India-based Curadev’s March 2020 licensing agreement with Bayer for the discovery and production of novel interferon gene stimulators (STING) antagonists across indications with high unmet need indicates the importance of the STING mechanism for research by top pharmaceutical companies. As part of the partnership, Bayer acquires exclusive access to the software of novel STING antagonists. The firms will jointly develop new drugs for lung cancer, cardiovascular disease and other inflammatory diseases. In 2019 Curadev approved Takeda’s STING agonist software (CRD5500). Under the deal, in addition to research funding, Curadev will receive…

Jakob Lindberg, CEO of Oncopeptides @oncopeptides discusses the next steps for the ongoing trial once they receive FDA approval and provides insight into the lighthouse clinical trial. ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.   Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background on this news, Oncopeptides hosted a…

Jakob Lindberg, CEO of Oncopeptides @oncopeptides answers where does melphalan flufenamide fit in the mix of RRMM treatment if broad-spectrum agents dominate? ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.   Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background on this news, Oncopeptides hosted a webcast today to provide an…

OneOncology, the national association of independent group oncologists, said today that enrolling patients at their affiliate practices in clinical trials has increased marginally in March and April, just as the COVID-19 pandemic struck our communities hardest.  Clinical trial accruals occurred at a steady to slightly higher pace at OneOncology partner practices in March and April, while news outlets reported hundreds of clinical trials across the country have been suspended since March 1 due to the outbreak, especially in hospital-based settings that are disproportionately affected by the pandemics. “Elective medical procedures have stopped, but caring for cancer patients isn’t elective,” said…

Jakob Lindberg, CEO of Oncopeptides @oncopeptides discusses results of the HORIZON phase 2 data in RRMM. ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.   Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background on this news, Oncopeptides hosted a webcast today to provide an update on the final study results…

Jakob Lindberg, CEO of Oncopeptides @oncopeptides explains the combination of the pivotal phase 2 study, HORIZON and phase 3 study, OCEAN, becoming key studies for melphalan flufenamide in the US and the EU. ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.   Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background…

Jakob Lindberg, CEO of Oncopeptides @oncopeptides explains the significance of the latest data findings from the O-12-M1 clinical trial recently published. ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.   Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background on this news, Oncopeptides hosted a webcast today to provide an update…

Jakob Lindberg, CEO of Oncopeptides @oncopeptides discusses the 5 clinical trials for the treatment of relapsed/refractory multiple myeloma: O-12-M1, Horizon, Ocean, Anchor and Bridge. ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.   Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background on this news, Oncopeptides hosted a webcast today to…

Ron Peck, MD, CMO of Arvinas @Arvinas on the orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat men with metastatic prostate cancer, and ARV-471, a potential treatment for patients with locally advanced or metastatic breast cancer. The results of both trials showed a favorable overall safety profile, and exposures reaching levels predicted by preclinical studies to be efficacious. The company will report initial efficacy data this year, which will be a huge step in proving the concept of PROTAC protein degraders as drugs. Degradation of proteins has a major therapeutic promise: PROTAC protein degraders can remove almost all of a…

Ron Peck, MD, CMO of Arvinas @Arvinas answers common questions on the orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat men with metastatic prostate cancer, and ARV-471, a potential treatment for patients with locally advanced or metastatic breast cancer. The results of both trials showed a favorable overall safety profile, and exposures reaching levels predicted by preclinical studies to be efficacious. The company will report initial efficacy data this year, which will be a huge step in proving the concept of PROTAC protein degraders as drugs. Degradation of proteins has a major therapeutic promise: PROTAC protein degraders can remove almost…

Ron Peck, MD, CMO of Arvinas @Arvinas discusses the initial safety and PK data on an orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat men with metastatic prostate cancer, and ARV-471, a potential treatment for patients with locally advanced or metastatic breast cancer. The results of both trials showed a favorable overall safety profile, and exposures reaching levels predicted by preclinical studies to be efficacious. The company will report initial efficacy data this year, which will be a huge step in proving the concept of PROTAC protein degraders as drugs. Degradation of proteins has a major therapeutic promise: PROTAC protein…

Ron Peck, MD, CMO of Arvinas @Arvinas discusses an orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat men with metastatic prostate cancer, and ARV-471, a potential treatment for patients with locally advanced or metastatic breast cancer. Dr. Peck further explains the approach to targeted protein degradation and why it might have potential in oncology. The results of both trials showed a favorable overall safety profile, and exposures reaching levels predicted by preclinical studies to be efficacious. The company will report initial efficacy data this year, which will be a huge step in proving the concept of PROTAC protein degraders as…

Dr. Mark Tuthill, MD of University of Oxford explains the ADVANCE, Phase 2a data, testing VTP-800 on prostate cancer immunotherapy and the key steps to phase 3. _____________ Vaccitech Limited and Oxford University today revealed initial efficacy and safety results for ADVANCE, a Phase 2a research testing VTP-800, a candidate for immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). The study showed that the VTP-800 is safe and showed an positive trend in efficacy in mCRPC patients. ADVANCE (NCT03815942) is an open-label, non-randomized research sponsored and performed by the University of Oxford, funded by the FP7 and Vaccitech programs…

Dr. Mark Tuthill, MD of University of Oxford answers the ADVANCE, Phase 2a data, testing VTP-800 on prostate cancer immunotherapy: are they accepting new patients for the study? _____________ Vaccitech Limited and Oxford University today revealed initial efficacy and safety results for ADVANCE, a Phase 2a research testing VTP-800, a candidate for immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). The study showed that the VTP-800 is safe and showed an positive trend in efficacy in mCRPC patients. ADVANCE (NCT03815942) is an open-label, non-randomized research sponsored and performed by the University of Oxford, funded by the FP7 and Vaccitech…

Dr. Mark Tuthill, MD of University of Oxford discusses the ADVANCE, Phase 2a data, testing VTP-800 on prostate cancer immunotherapy. _____________ Vaccitech Limited and Oxford University today revealed initial efficacy and safety results for ADVANCE, a Phase 2a research testing VTP-800, a candidate for immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). The study showed that the VTP-800 is safe and showed an positive trend in efficacy in mCRPC patients. ADVANCE (NCT03815942) is an open-label, non-randomized research sponsored and performed by the University of Oxford, funded by the FP7 and Vaccitech programs of the European Commission. The research aims…

Dr. James Bates, MD @JamesBatesMD of University of Florida @UF answers is this reflective of long term techniques on long term outcomes in 10-year survivors of early-stage hodgkin lymphoma. ___________ Although radiation therapy enhances progression-free survival in early-stage Hodgkin lymphoma (HL), significant questions remain about the effect on quality of life and survival of delayed normal tissue impacts. We hypothesized that combined-modality therapy (CMT; chemotherapy and radiation therapy) care increases overall survival among 10-year survivors as opposed to radiation therapy or chemotherapy care alone.

Dr. James Bates, MD @JamesBatesMD of University of Florida @UF discusses long term outcomes in 10-year survivors of early-stage hodgkin lymphoma. ________ Although radiation therapy enhances progression-free survival in early-stage Hodgkin lymphoma (HL), significant questions remain about the effect on quality of life and survival of delayed normal tissue impacts. We hypothesized that combined-modality therapy (CMT; chemotherapy and radiation therapy) care increases overall survival among 10-year survivors as opposed to radiation therapy or chemotherapy care alone.

Rosario Campelo, MD of University Hospital of A Coruña discusses ALUNBRIG (brigatinib) as a first-line treatment for ALK + non-small cell lung cancer. ______________ ALUNBRIG’s Phase 3 ALTA-1L (ALK in BrigAtinib’s Lung Cancer Trial in 1st line) study in adults is a global, ongoing, randomized, open-label, comparative, multicenter study that enrolled 275 patients (ALUNBRIG, n=137, crizotinib, n=138) with ALK+ locally advanced or metastatic NSCLC who did not receive an ALK inhibitor prior care. Patients received either ALUNBRIG, 180 mg once daily at 90 mg once daily with seven-day lead-in, or crizotinib, 250 mg twice daily. In the ALUNBRIG arm the…

Rosario Campelo, MD of University Hospital of A Coruña discusses ALUNBRIG (brigatinib) as a first-line treatment for ALK + non-small cell lung cancer. What is Intracranial Efficacy in ALUNBRIG for ALK + NSCLC? ______________ ALUNBRIG’s Phase 3 ALTA-1L (ALK in BrigAtinib’s Lung Cancer Trial in 1st line) study in adults is a global, ongoing, randomized, open-label, comparative, multicenter study that enrolled 275 patients (ALUNBRIG, n=137, crizotinib, n=138) with ALK+ locally advanced or metastatic NSCLC who did not receive an ALK inhibitor prior care. Patients received either ALUNBRIG, 180 mg once daily at 90 mg once daily with seven-day lead-in, or…